Treating multiple sclerosis with natalizumab

Expert Review of Neurotherapeutics

Volumn 11, Issue 12, 2011, Pages 1683-1692

  Iaffaldano, Pietro ^a   Lucchese, Guglielmo ^a   Trojano, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

monoclonal antibody; multiple sclerosis; natalizumab; post marketing; progressive multifocal leukoencephalopathy

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; FINGOLIMOD; GLATIRAMER; GYLENIA; METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CONTINUOUS INFUSION; DISEASE ACTIVITY; DISEASE COURSE; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEMATOPOIESIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INSOMNIA; LEUKOCYTE MIGRATION; LIVER INJURY; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PREGNANCY OUTCOME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RECURRENCE RISK; RELAPSE; RISK FACTOR; SERUM SICKNESS; SURVIVAL RATE; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS MENINGITIS; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS;

EID: 81755187644     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.154     Document Type: Article

References (78)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000).
2. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7(3), 115-121 (2001).
3. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338(5), 278-285 (1998).
4. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12(3), 295-302 (1999).
5. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14(3), 271-278 (2001).
6. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3(4), 291-301 (2002).
7. The IFNB Multiple Sclerosis Study Group. Interferon b-1b is effective in relapsing- remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-βlind, placebo controlled trial. Neurology 43, 655-661 (1993).
8. The IFNb Multiple Sclerosis Study Group and The Univesity of British Columbia MS/MRI Analysis Group. Interferon b-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-1285 (1995).
9. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon b-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39, 285-294 (1996).
10. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-βlind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498-1504 (1998).
11. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a Phase III multicenter, double-βlind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268-1276 (1995).
12. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74(18), 1463-1470 (2010).
13. Rudick RA, Cutter GR, Baier M et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult. Scler. 11(6), 626-634 (2005).
14. Bermel RA, Weinstock-Guttman B, Bourdette D et al. Intramuscular interferon b-1a therapy in patients with relapsing- remitting multiple sclerosis: a 15-year follow-up study. Mult. Scler. 16(5), 588-596 (2010).
15. Kappos L, Traboulsee A, Costantinescu C et al. Long-term subcutaneously interferon b-1a therapy in patients with relapsing-remitting MS. Neurology 67, 944-953 (2006).
16. Ebers GC, Rice G, Konieczny A et al. The interferon b-1b 16-year long-term follow-up study: the final results. Neurology 66(Suppl. 2), A32 (2006).
17. Ebers GC, Traboulsee A, Li D et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNb-1b trial. J. Neurol. Neurosurg. Psychiatry 81(8), 907-912 (2010).
18. Johnson KP, Brooks BR, Ford CC et al. Glatiramer acetate (Copaxone), comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler. 9(6), 585-591 (2003).
19. Johnson KP, Ford CC, Lisak RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol. Scand. 111(1), 42-47 (2005).
20. Ford CC, Johnson KP, Lisak RP et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult. Scler. 12(3), 309-320 (2006).
21. Ford C, Goodman AD, Johnson K et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler. 16(3), 342-350 (2010).
22. Trojano M, Pellegrini F, Fuiani A et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann. Neurol. 61(4), 300-306 (2007).
23. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon b-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911-923 (2006).
24. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
25. Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353(4), 362-368 (2005).
26. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924-933 (2006).
27. Iaffaldano P, D'Onghia M, Trojano M. Safety profile of Tysabri: international risk management plan. Neurol Sci. 30(Suppl. 2), S159-S162 (2009).
28. Kivisäkk P, Healy BC, Viglietta V et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72(22), 1922-1930 (2009).
29. Stüve O, Marra CM, Jerome KR et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59(5), 743-747 (2006).
30. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-β and B cells in multiple sclerosis. Neurology 71(17), 1350-1354 (2008).
31. Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult. Scler. 16(2), 208-217 (2010).
32. Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J. Clin. Immunol. 31(4), 623-631 (2011).
33. Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of Blood cell subpopulations of multiple sclerosis patients. J. Neuroimmunol. 194(1-2), 153-164 (2008).
34. Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. a4-Integrin antagonism with natalizumab: effects and adverse effects. J. Neurol. 255(Suppl. 6), 58-65 (2008).
35. + T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol. 65(12), 1596-1603 (2008).
36. Labrijn AF, Buijsse AO, van den Bremer ET et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 27(8), 767-771 (2009).
37. Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
38. Rispens T, Leeuwen A, Vennegoor A et al. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal. Biochem. 411(2), 271-276 (2011).
39. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52(5), 1072-1074 (1999).
40. Rudick RA, Sandrock A. Natalizumab: 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother. 4(4), 571-580 (2004).
41. Tubridy N, Behan PO, Capildeo R et al. The effect of anti-4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53(3), 466-472 (1999).
42. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology 74(Suppl. 3), S3-S7 (2010).
43. Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 8(3), 254-260 (2009).
44. Phillips JT, Giovannoni G, Lublin FD et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult. Scler. doi:10.1177/1352458511399611 (2011) (Epub ahead of print).
45. Hellwig K, Schimrigk S, Fischer M et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch. Neurol. 65(5), 656-658 (2008).
46. Goodman AD, Rossman H, Bar-Or A et al. GLANCE: results of a Phase II, randomized, double-βlind, placebo-controlled study. Neurology 72(9), 806-812 (2009).
47. Wiendl H, Belachew S, Butzkueven H et al. Assessment of the association between baseline characteristics and postbaseline relapses, disability progression and improvement over time in the natalizumab (TYSABRI®) Observational Program (TOP) in patients with multiple sclerosis. Presented at: 63rd Congress of the American Academy of Neurology. Honolulu, Hawaii, USA, 9-16 April, 2011.
48. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9(4), 425-437 (2010).
49. + hematopoietic progenitor cells in humans. Blood 111(7), 3893-3895 (2008).
50. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol. 70(10), 7004-7012 (1996).
51. + cells during mobilization with G-CSF. Bone Marrow Transplant 23(1), 1-8 (1999).
52. Yaldizli O, Putzki N. Natalizumab in the treatment of multiple sclerosis. Ther. Adv. Neurol. Disord. 2(2), 115-128 (2009).
53. Warnke C, Menge T, Hartung HP et al. Natalizumab and progressive multifocal leukoencephalopathy. Arch. Neurol. 67(8), 923-930 (2010).
54. Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 68(3), 295-303 (2010).
55. Bloomgren G, Sandrock A, Hotermans C et al. Risk stratification for progressive multifocal leukoencephalopathy in multiple sclerosis patients using natalizumab. Presented at: 21st Meeting of the European Neurological Society. Lisbon, Portugal, 28-31 May, 2011.
56. Vermersch P, Kappos L, Gold R et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76(20), 1697-1704 (2011).
57. Stüve O, Marra CM, Cravens PD et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch. Neurol. 64(2), 169-176 (2007).
58. Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother. 53(5), 1840-1849 (2009).
59. Elphick GF, Querbes W, Jordan JA et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306(5700), 1380-1383 (2004).
60. Clifford D, Nath A, Cinque P et al. Mefloquine treatment in patients with progressive multifocal leukoencephalopathy. Presented at: 63rd Congress of the American Academy of Neurology. Honolulu, Hawaii, USA, 9-16 April 2011.
61. O'Connor PW, Goodman AD, Kappos L et al. Updated efficacy and safety of natalizumab in patients who participated in the STRATA study. Presented at: 26th Congress of the European Committee for treatment and research in Multiple Sclerosis. Gothemburg, Sweden, 13-16 October 2010.
62. Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult. Scler. 15(12), 1532-1533 (2009).
63. Castela E, Lebrun-Frenay C, Laffon M et al. Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch. Dermatol. 147(1), 72-76 (2011).
64. Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann. Neurol. 66(3), 403-406 (2009).
65. Bozic C, LaGuette J, Panzara MA, Sandrock AW. Natalizumab and central nervous system lymphoma: no clear association. Ann. Neurol. 66(3), 261-262 (2009).
66. Phan-βa R, Bisig B, Deprez M et al. Primary central nervous system lymphoma in a patient treated with Natalizumab. Ann. Neurol. 69(6), 1060-1061 (2011).
67. Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol. Ther. 31(9), 1028-1035 (2010).
68. Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an a4 integrin inhibitor. Birth Defects Res. B Dev. Reprod. Toxicol. 86(2), 117-130 (2009).
69. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an a4 integrin inhibitor. Birth Defects Res. B Dev. Reprod. Toxicol. 86(2), 144-156 (2009).
70. Cristiano LM, Bozic C, Bloomgren G, Kooijmans-Coutinho M. Preliminary evaluation of prospective pregnancy outcomes from the TYSABRI® (natalizumab) pregnancy registry. Presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Gothemburg, Sweden, 13-16 October 2010.
71. Ghezzi A, Pozzilli C, Grimaldi LM et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75(10), 912-917 (2010).
72. Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther. Adv. Neurol. Disord. 3(5), 293-299 (2010).
73. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch. Neurol. 68, 186-191 (2011).
74. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70(13 Pt 2), 1150-1151 (2008).
75. O'Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76, 1858-1865 (2011).
76. Ghezzi A, Grimaldi LM, Marrosu MG et al. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group - Italian Neurological Society. Neurol. Sci. 32(2), 351-358 (2011).
77. Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
78. Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 6, 431-441 (2007).